The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 26, 2023

Filed:

Jul. 05, 2017
Applicant:

The Johns Hopkins University, Baltimore, MD (US);

Inventors:

Vinod Jaskula-Ranga, Cambridge, MA (US);

Donald Zack, Baltimore, MD (US);

Derek Welsbie, Baltimore, MD (US);

Assignee:

The Johns Hopkins University, Baltimore, MD (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); A61K 9/00 (2006.01); C12N 15/86 (2006.01);
U.S. Cl.
CPC ...
A61K 48/005 (2013.01); A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); C12N 15/86 (2013.01); C12N 2310/20 (2017.05); C12N 2330/51 (2013.01); C12N 2710/10344 (2013.01); C12N 2750/14143 (2013.01);
Abstract

The presently disclosed subject matter provides compositions and methods comprising improvements of a CRISPR system (e.g. CRISPR associated (Cas) 9 (CRISPR-Cas9, non-Cas9 CRISPR systems). Such compositions may comprise modifications to the H1 promoter region, addition of 5'UTR modifications, different orthologous sequences of the H1 promoter, novel compact bidirectional promoter sequences with both pol II and pol III activity, addition of Kozak consensus sequences, termination sequences, addition of conditional pol II/pol III bidirectional promoter expression, addition of a donor template sequence for correcting mutations, or combinations thereof. Other aspects of the invention relate to modifications to Cas9 through post-transcriptional cell-cycle regulation fusions, engineered partial target sites such that the nuclease can bind without DNA cleavage, auto-regulation sites, and N-terminal modifications to modulate half-life.


Find Patent Forward Citations

Loading…